Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts

Clinical and Experimental Gastroenterology

Volumn 8, Issue , 2014, Pages 13-29

  Cheng, Michelle ^a   Ho, Samantha ^a   Yoo, Jun Hwan ^a,b   Tran, Deanna Hoang Yen ^a   Bakirtzi, Kyriaki ^a   Su, Bowei ^a   Tran, Diana Hoang Ngoc ^a   Kubota, Yuzu ^a   Ichikawa, Ryan ^a   Koon, Hon Wai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHA University   (South Korea)

Author keywords

Colon cancer; Epithelial mesenchymal transition; Fibroblasts

Indexed keywords

AZOXYMETHANE; CATHELICIDIN; DEXTRAN SULFATE; TRANSFORMING GROWTH FACTOR BETA1; TUBULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84919701468     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S70906     Document Type: Article

References (40)

1. Ho S, Pothoulakis C, Koon HW. Antimicrobial peptides and colitis. Curr Pharm Des. 2012;19:40-47.
2. Hing TC, Ho S, Shih DQ, et al. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut. 2012;62:1295-1305.
3. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood). 2007;232:799-808.
4. Tai EK, Wu WK, Wang XJ, et al. Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp(-/-) mice. Gene Ther. 2012;20:187-193.
5. Wong CC, Zhang L, Li ZJ, et al. Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. J Gastroenterol Hepatol. 2012;27:1205-1212.
6. Scott A, Weldon S, Buchanan PJ, et al. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One. 2011;6:e26525.
7. Ruan Y, Shen T, Wang Y, Hou M, Li J, Sun T. Antimicrobial peptide LL-37 attenuates LTA induced inflammatory effect in macrophages. Int Immunopharmacol. 2013;15:575-580.
8. Wu WK, Sung JJ, Cheng AS, et al. The Janus face of cathelicidin in tumorigenesis. Curr Med Chem. 2014;21:2392-2400.
9. Wu WK, Wang G, Coffelt SB, et al. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer. 2010;127:1741-1747.
10. Heilborn JD, Nilsson MF, Jimenez CI, et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 2005;114:713-719.
11. Coffelt SB, Waterman RS, Florez L, et al. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer. 2008;122:1030-1039.
12. von Haussen J, Koczulla R, Shaykhiev R, et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2008;59:12-23.
13. Ren SX, Cheng AS, To KF, et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 2012;72:6512-6523.
14. Wu WK, Sung JJ, To KF, et al. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol. 2010;223:178-186.
15. Ren SX, Shen J, Cheng AS, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One. 2013;8:e63641.
16. Kuroda K, Fukuda T, Okumura K, et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs. 2013;24:826-834.
17. Kuroda K, Fukuda T, Yoneyama H, et al. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53. Oncol Rep. 2012;28:829-834.
18. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
19. Koon HW, Shih D, Karagiannides I, et al. Substance P modulates colitis-associated fibrosis. Am J Pathol. 2010;177:2300-2309.
20. Koon HW, Shih DQ, Chen J, et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology. 2011;141(1852-1863):e1-e3.
21. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
22. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem. 2004;279:45519-45527.
23. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116:1955-1962.
24. Duckworth CA, Clyde D, Worthley DL, Wang TC, Varro A, Pritchard DM. Progastrin-induced secretion of insulin-like growth factor 2 from colonic myofibroblasts stimulates colonic epithelial proliferation in mice. Gastroenterology. 2013;145(197-208):e3.
25. Herrera A, Herrera M, Alba-Castellon L, et al. Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells. Int J Cancer. 2014;134(12):2984-2990.
26. Todosi AM, Gavrilescu MM, Anitei GM, Filip B, Scripcariu V. Colon cancer at the molecular level - usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi. 2012;116:1106-1111.
27. Cai ZG, Zhang SM, Zhang H, Zhou YY, Wu HB, Xu XP. Aberrant expression of microRNAs involved in epithelial-mesenchymal transition of HT-29 cell line. Cell Biol Int. 2013;37:669-674.
28. Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med. 2008;22:271-275.
29. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10:194-204.
30. Amos LA, Lowe J. How Taxol stabilises microtubule structure. Chem Biol. 1999;6:R65-R69.
31. Hirose A, Tajima H, Ohta T, et al. Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. Oncol Lett. 2013;6:915-920.
32. Tsukada T, Fushida S, Harada S, et al. Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. Int J Oncol. 2013;42:1167-1174.
33. Wang C, Song X, Li Y, et al. Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation. PLoS One. 2013;8:e70725.
34. Ngan CY, Yamamoto H, Seshimo I, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer. 2007;96:986-992.
35. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1:482-497.
36. Visco V, Bava FA, d'Alessandro F, Cavallini M, Ziparo V, Torrisi MR. Human colon fibroblasts induce differentiation and proliferation of intestinal epithelial cells through the direct paracrine action of keratinocyte growth factor. J Cell Physiol. 2009;220:204-213.
37. Watanabe M, Ishiwata T, Nishigai K, Moriyama Y, Asano G. Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer. Pathol Int. 2000;50:363-372.
38. Zhu L, Cheng X, Ding Y, et al. Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett. 2013;343:80-89.
39. Ahluwalia A, Tarnawski AS. Cathelicidin gene therapy: a new therapeutic option in ulcerative colitis and beyond? Gene Ther. 2012;20:119-120.
40. Zhang L, Yu J, Wong CC, et al. Cathelicidin protects against Helicobacter pylori colonization and the associated gastritis in mice. Gene Ther. 2012;20:751-760.